LENZ Therapeutics (LENZ) Cash & Equivalents (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Cash & Equivalents data on file, last reported at $24.8 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 7.51% year-over-year to $24.8 million in Q1 2026; TTM through Mar 2026 was $24.8 million, a 7.51% increase from a year earlier, with the FY2025 full-year figure at $25.2 million, up 24.91% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $24.8 million, down from $25.2 million in the prior quarter.
• Over the last five years, Cash & Equivalents for LENZ reached as high as $200.4 million in Q1 2024 and fell as low as $8.0 million in Q1 2023.
• Historically, Cash & Equivalents has averaged $72.1 million across 5 years, with a median of $39.3 million in 2024.
• Across the five-year window, Cash & Equivalents tumbled 95.7% in 2023 and jumped 2416.42% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $56.4 million in 2022, then slumped by 37.69% to $35.1 million in 2023, then sank by 42.64% to $20.2 million in 2024, then gained by 24.91% to $25.2 million in 2025, then dropped by 1.62% to $24.8 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $24.8 million in Q1 2026, $25.2 million in Q4 2025, and $25.4 million in Q3 2025.